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Abstract
Introduction: Coronary artery disease (CAD) and vascular erectile dysfunction
(ED) are related to endothelial dysfunction. Elevated asymmetrical
dimethylarginine (ADMA) levels and ED are common in patients with increased
cardiovascular risk. Our aim was to investigate whether ADMA has a predictive
role for major adverse cardiovascular events (MACE) in acute coronary syndrome
(ACS). The secondary aim of this study was to investigate whether severity of
ED predicts MACE in these patients.
Material and methods: Follow-up data were available for severity of ED in 71 patients
with ACS. Plasma ADMA levels were determined by ELISA in 57 patients. Erectile
dysfunction was assessed by the International Index of Erectile Function-6 
(IIEF-6) score. Major adverse cardiovascular events (reinfarction, all-cause
hospitalisation, stroke and all-cause death) was evaluated after a median of 
10 months.
Results: Severe ED had no significantly increased hazard ratio for cardiovascular
events compared with mild, mild to moderate, and moderate ED (0.259 [95% CI
0.041-1.6], p = 0.147; 0.605 [95% CI 0.095-3.8], p = 0.594; 0.980 [95% CI 0.233-4.1],
p = 0.978; and 0.473 [95% CI 0.052-1.3], p = 0.508). The patients who had ADMA
levels ≥ 0.32 µmol/l had no significantly increased hazard ratio for cardiovascular
events compared with patients who had ADMA levels < 0.32 µmol/l (2.018 [95% CI
0.615-6.6], p = 0.247).
Conclusions: Severity of ED and ADMA did not increase the risk of cardiovascular
events in follow-up patients with ACS in our study. Larger prospective studies
are necessary to evaluate whether ADMA predicts cardiovascular events in
patients with ACS.
Key words: acute coronary syndrome, asymmetric dimethylarginine, erectile
dysfunction, major adverse cardiovascular events.
Introduction
Erectile dysfunction (ED) is associated with increased vascular risk of
coronary heart disease and stroke [1]. Increased prevalence rates of ED
have been reported in patients with vascular disorders such as myocardial
infarction and stroke [2]. Men with ED have a two-fold increased risk for
acute myocardial infarction [3]. Because ED is a marker of subclinical
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coronary artery disease (CAD), many ED patients
carry a risk of acute coronary syndrome (ACS).
Although the association between cardiovascular
risk factors and ED is well established, the predictive
role of ED for future cardiovascular events in CAD
patients who present with ACS is not known clearly.
Asymmetrical dimethylarginine (ADMA) has
recently aroused interest as an endogenous
competitive inhibitor of nitric oxide synthases and
an independent marker for cardiovascular disease
[4]. Generated ADMA is dependent on the extent
of arginine methylation in proteins and in the rates
of protein turnover and it is extensively metabolized
by dimethylarginine dimethylaminohydrolase [5]. It
has the potential to produce considerable biological
effects, particularly in the endothelial system. Over
the last years, several studies have suggested that
plasma concentrations of ADMA provide a marker
of risk for endothelial dysfunction [6]. Asymmetrical
dimethylarginine levels are significantly elevated in
men who have early stage coronary atherosclerosis
and ED [7]. Assessment of ADMA might aid
cardiovascular risk assessment. We investigated
whether ADMA has a predictive role for major
adverse cardiovascular events (MACE) in CAD
patients who presented with ACS. The secondary
aim of this study was to investigate whether
severity of ED predicts MACE in these patients. 
Material and methods
A total of 121 men who presented with ACS 
and underwent coronary angiography were
prospectively enrolled between January 2007 and
July 2007 for this study. Thirty-one patients refused
participation or returned the International Index
of Erectile Function-6 (IIEF-6) questionnaire
incomplete. After evaluation of exclusion criteria
(heart failure, end stage renal failure, severe valvular
heart disease, concomitant chronic severe disease),
90 patients were enrolled into the ongoing study.
In 20 patients laboratory values for ADMA were
missing and 13 patients’ follow-up data of MACE
were not available. Asymmetrical dimethylarginine
analysis was performed for the remaining 57
patients. For analysis of ED severity, 19 patients’
follow-up data of MACE were not available. The
remaining 71 subjects with complete baseline and
follow-up data were included in the analysis. 
Inclusion criteria for ACS were: chest pain
consistent with myocardial ischaemia, elevation of
troponin-I or creatine kinase above upper limit of
normal, and one of the following findings:
electrocardiographic evidence of ischaemia, or wall
motion abnormality. At the time of inclusion,
demographic data, clinical characteristics and current
medications were recorded. All patients were
evaluated with physical examination and underwent
laboratory tests, including lipid profile and fasting
glucose. Risk factors were defined as follows:
hypertension as blood pressure > 140/90 mm Hg or
taking antihypertensive drugs; hypercholesterolaemia
as total cholesterol level > 190 mg/dl and LDL
cholesterol level > 130 mg/dl; diabetes as fasting
glucose level > 125 mg/dl or taking antidiabetic drugs.
The study protocol was approved by the Local Ethics
Committee and all patients gave informed consent.
Assessment of erectile dysfunction
Erectile dysfunction was assessed by the IIEF-6
score [8]. All men were asked to complete the IIEF
questionnaire. Erectile function is addressed by 
6 questions. Each question is scored 0 to 5. Erectile
dysfunction is defined as value < 26. The severity
of ED was classified into 5 categories: no ED (IIEF
score 26 to 30), mild (IIEF score 22 to 25), mild to
moderate (IIEF score 17 to 21), moderate (IIEF score
11 to 16), and severe (IIEF score < 10) [8].
Assessment of coronary artery involvement
Coronary angiography was carried out in all
patients by the Judkins standard technique.
Significant angiographic narrowing was defined as
> 50% diameter stenosis. Coronary artery disease
was scored with 1-2-3 vessel disease. Our study
included cases with ACS, and because of acute total
occlusion, previously modified Gensini score was
used for coronary artery involvement [9]. 
Laboratory investigations
After an overnight fast, venous blood was
collected and serum separated and stored at –70°C
until batch analysis. All blood samples were taken
within 1 week of diagnosis of ACS and before
coronary angiography. Blood levels of blood glucose,
total cholesterol, HDL cholesterol, LDL cholesterol
and triglycerides were measured by standard
laboratory methods. ADMA was analysed by 
the ELISA method (ADMA direct ELISA, Im  mun  -
diagnostik AG, Bensheim, Germany) according to the
manufacturer’s guidelines.
Study end points and follow-up
The study end point was the occurrence of a first
MACE consisting of reinfarction, re-hospitalisation,
stroke and all cause death. All patients were then
prospectively followed by office visit or by telephone
contact at 3-month intervals for the occurrence of
first MACE. Outcome was evaluated by 2 observers
(M. A., A. B.) who were blinded with respect to the
patients’ baseline clinical and laboratory data.
Statistical analysis
Continuous data are presented as medians (min-
max values) for both ADMA and IIEF-6 score.
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Categorical data are given as counts (percentages).
Mann-Whitney U test was applied for univariate
comparison of continuous data and Spearman rank
correlation for assessment of associations between
continuous variables. ROC analysis was used for
ADMA cut-off values. Event-free survival rates until
the first cardiovascular adverse event according to
ADMA levels (ROC analysis) and IIEF score were
calculated using the Kaplan-Meier method and
compared by the log rank test. Multivariate Cox
proportional hazards analysis was used to assess
the independent effect of ADMA and IIEF on the
composite end point and to adjust for potential
confounders. Continuous variables were included
as confounders if these variables were associated
with ADMA and IIEF according to Spearman rank
correlation coefficients. Categorical variables were
entered into the model if they influenced ADMA
and IIEF according to univariate analysis. In addition,
adjustment for traditional cardiovascular risk factors
was performed. Results of the Cox proportional
hazards model are presented as hazard ratio and
95% confidence interval (CI) as well as survival
curves according to cut-off values of ADMA and IIEF.
P values < 0.05 were considered to indicate
statistical significance. 
According to a retrospective power analysis for
ADMA level in patients, when 57 patients and 
HR = 2.018 are used, power is calculated as 0.275
(α = 0.05). Data were analysed using NCSS 2008
Demo for Windows (NCSS, Kaysville, UT, USA).
Results
Ninety patients were eligible for the study. In 20
patients laboratory values for ADMA were missing
and 13 patients’ follow-up data of MACE were not
available. Asymmetrical dimethylarginine analysis
was performed for the remaining 57 patients. For
analysis of ED severity, 19 patients’ follow-up data
of MACE were not available. The remaining 71
subjects with complete baseline and follow-up data
were included in the analysis. Follow-up duration
was median 10 months (range: 1-13 months).
Asymmetrical dimethylarginine and survival
Median ADMA plasma concentration of all
patients was 0.50 µmol/l (IQR, 0.06 to 1.41). Factors
potentially influencing ADMA concentrations such
as the presence of risk factors of atherosclerosis,
medication, coronary vessels involvement, and
revascularisation were not significantly different
(Table I). Asymmetrical dimethylarginine was
elevated in the patients without diabetes mellitus
and the group without antidiabetic therapy and
correlated negatively with age and Gensini score
(Table II). During follow-up, 5.3% reinfarction, 12.3%
hospitalisation, and 8.8% all-cause death occurred
in 57 patients, and the revascularisation rate was
63.2%. When the cut-off value of ADMA 0.32 µmol/l
was accepted according to ROC analysis, > 0.32
µmol/l yielded a sensitivity of 70% and a specificity
of 28% for detecting CAD which presented ACS.
Thus, according to ADMA cut-off value 0.32 µmol/l,
57 subjects were divided into 2 groups. Twenty-nine
percent MACE in the patients who had ADMA levels
< 0.32 µmol/l and 17.5% MACE in other patients
occurred during the follow-up period (p = 0.236, 
χ2 = 1.405, log rank test). The patients who had
ADMA levels ≥ 0.32 µmol/l had no significantly
increased hazard ratio for cardiovascular events
compared with patients who had ADMA levels 
< 0.32 µmol/l after adjustment for possible
confounders (2.018 [95% CI 0.615-6.626], p = 0.247
(Table III).
Severity of erectile dysfunction and survival
During follow-up 20 (28.5%) MACE occurred in
71 patients including 7.1% reinfarction, 14.3%
hospitalisation, and 7.1% all-cause death, and the
revascularisation rate was 64.3%. When patients
were divided into 5 groups according to severity of
ED, no ED had no significantly increased hazard
ratio for cardiovascular events compared with mild,
mild to moderate, moderate ED, and severe ED after
adjustment for possible confounders (0.259 
[95% CI 0.041-1.610], p = 0.147; 0.605 [95% CI 0.095-
3.843], p = 0.594; 0.980 [95% CI 0.233-4.121], 
p = 0.978; 0.473 [95% CI 0.052-1.345], p = 0.508,
respectively). (According to multivariate Cox
regression analysis) (Table IV).
Discussion
Our findings showed that serum ADMA
concentrations and severity of ED did not predict
major cardiovascular events after adjustment of
confounder factors in patients with CAD who
presented with ACS in this study population. No
difference, in terms of serum ADMA and severity of
ED, was seen between the MACE group and the
group without MACE.
Over the last decade, several studies have shown
that circulating concentrations of ADMA can be
influenced by many factors. Treatment with
rosuvastatin [10], rosiglitazone, metformin, ACE
inhibitors and AT-2 receptor blockers have
decreased ADMA concentrations in humans [11, 12].
In addition, ADMA is a well characterized marker
that has been associated with many traditional risk
factors and vascular disorders, as demonstrated for
hypertension [13], hyperhomocysteinaemia [14],
peripheral artery disease [15], and stroke [16].
Barylski et al. [17] showed that renal failure may be
related to impaired endothelial function. Vallance
et al. [18] demonstrated that accumulation of
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N ADMA [µmol/l] P value N IIEF (score) P value
Risk factors
Hypertension
Yes 21 0.44 (0.06-1.30) 26 18 (1-30)
No 36 0.55 (0.09-1.41) 0.155 44 20 (1-30) 0.363        
Diabetes mellitus
Yes 9 0.16 (0.06-0.84) 15 11 (1-26)
No 48 0.54 (0.09-1.41) 0.001 53 21 (1-30) 0.002
Hyperlipidaemia
Yes 6 0.34 (0.08-0.71) 7 26 (15-30)
No 51 0.50 (0.06-1.41) 0.233 63 19 (1-30) 0.116
Smoking current
Yes 33 0.55 (0.09-1.41) 41 20 (1-30)
No 24 0.45 (0.06-1.28) 0.070 29 15 (1-30) 0.031
Smoking former
Yes 46 0.50 (0.08-1.41) 57 19 (1-30)
No 11 0.47 (0.06-1.28) 0.537 13 20 (1-30) 0.867
Medication
β-Blocker therapy
Yes 14 0.52 (0.08-1.13) 16 24 (1-30)
No 43 0.47 (0.06-1.41) 0.882 54 18.5 (1-30) 0.187
ACE inhibitors therapy
Yes 15 0.49 (0.06-1.30) 17 21 (1-30)
No 42 0.52 (0.08-1.41) 0.906 53 19 (1-30) 0.283
AT2 receptor blocker therapy
Yes 5 0.43 (0.08-0.97) 7 22 (1-30)
No 52 0.52 (0.06-1.41) 0.401 63 19 (1-30) 0.549
Calcium antagonist therapy
Yes 4 0.78 (0.38-1.13) 4 15.5 (1-28)
No 53 0.49 (0.06-1.41) 0.142 66 19.5 (1-30) 0.470
Diuretic therapy
Yes 1 1.30 (1.30-1.30) 1 30 (30-30)
No 56 0.49 (0.06-1.41) 0.070 69 19 (1-30) 0.143
Statin therapy
Yes 5 0.58 (0.28-1.13) 7 26 (9-30)
No 52 0.49 (0.06-1.41) 0.671 63 19 (1-30) 0.242
Acetylsalicylic acid therapy
Yes 18 0.46 (0.06-1.41) 20 21.5 (1-30)
No 39 0.54 (0.12-1.28) 0.589 50 19 (1-30) 0.293
Clopidogrel therapy
Yes 5 0.50 (0.28-1.13) 6 20.5 (1-30)
No 52 0.49 (0.06-1.41) 0.838 64 19 (1-30) 0.976
Table I. Median plasma concentrations (interquartile range) of ADMA and IIEF score grouped according to categorical
baseline variables
Erectile dysfunction and asymmetrical dimethylarginine in acute coronary syndromeMedian (min-max) ADMA P value Median (min-max) IIEF score P value
(R)( R)
Age [year] 58 (35-79) –0.301 0.02 58 (35-79) –0.635 0.000
Body mass index [kg/m2] 26.22 (18.8-42.59) –0.137 0.31 26.2 (18.8-42.6) 0.139 0.251
Cholesterol [mg/dl] 182 (86-278) –0.279 0.47 177.5 (86-326)    0.340 0.291
Triglycerides [mg/dl] 128 (50-410) 0.007 0.96 132 (40-410)     0.071 0.573
LDL cholesterol [mg/dl] 113 (29-214) –0.282 0.04 112 (29-320) 0.056 0.658
HDL cholesterol [mg/dl] 36 (22-50) –0.342 0.01 35 (22-50) 0.202 0.116
Ejection fraction [%] 50 (57-30.74) 0.102 0.48 57 (30-74) 0.080 0.541
Gensini score 33 (7-117)   –0.291 0.03 39 (7-122)    –0.309 0.009
IIEF score 21 (1-30) 0.247 0.06 19 (1-30) – –
ADMA [µmol/l] 0.50 (0.06-1.41) – –
Table II. Baseline characteristics and Spearman correlation coefficients (p value) for ADMA and IIEF score and
continuous variables of acute coronary syndrome
N ADMA [µmol/l] P value N IIEF (score) P value
Anticoagulant therapy
Yes 1 0.49 (0.49-0.49) 1 24 (24-24)
No 56 0.50 (0.06-1.41) 0.982 69 19 (1-30) 0.686
Oral antidiabetic therapy
Yes 6   0.06 (0.08-0.84) 9  12 (1-26)
No 51 0.54 (0.06-1.41) 0.017 61 20 (1-30) 0.032
Insulin therapy
Yes 3 0.15 (0.06-0.84) 3 1 (1-18)
No 54 0.50 (0.08-1.41) 0.259 67 20 (1-30) 0.058
Coronary vessels involvement
One-vessel disease
Yes 17 0.54 (0.16-1.28) 21 24 (1-30) 
No 40 0.47 (0.06-1.41) 0.958 49 18 (1-30) 0.053     
Two-vessel disease
Yes 18 0.61 (0.18-1.26) 20 18.5 (1-30)
No 39 0.47 (0.06-1.41) 0.066 50 20 (1-30) 0.527
Three-vessel disease
Yes 22 0.35 (0.06-1.41) 29 18 (1-30)
No 35 0.55 (0.16-1.28) 0.071 41 20 (1-30) 0.222
Total occlusion
Yes 13 0.38 (0.06-1.10) 15 18 (1-30)
No 44 0.54 (0.09-1.41) 0.068 55 20 (1-30) 0.499
Revascularisation 
Yes 36 0.43 (0.06-1.30) 45 21 (1-30)
No 21 0.54 (0.16-1.41) 0.317 25 15 (1-30) 0.056
Table I. Median plasma concentrations (interquartile range) of ADMA and IIEF score grouped according to categorical
baseline variables
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endogenous ADMA, as an indicator of endothelial
dysfunction, is associated with chronic renal failure.
In our study, factors potentially influencing
ADMA concentrations and prognosis after ACS were
not significantly different, such as the presence of
risk factors of atherosclerosis, medication, coronary
vessels involvement, revascularisation, and valve
disease. In our study, ADMA serum concentrations
were low in diabetic patients. This paradoxical
finding could in part be explained by administration
of oral antidiabetic therapy in half of the diabetic
population. Metformin and thiazolidinediones
reduce ADMA levels [19, 20]. Furthermore, our
results indicate that hypertension, hyperlipidaemia,
smoking, medications including β-blocker therapy,
ACE inhibitors and AT-2 blocker therapy, statins,
diuretics, calcium channel blockers and
antiaggregant therapy did not influence serum
ADMA concentrations. Asymmetrical dimethylar  -
ginine concentrations were not different in patients
on statin therapy or antihypertensive therapy in the
present cohort.
Since the demonstration that concentration of
ADMA acts as a marker of endothelial dysfunction,
circulating levels of ADMA have been related to the
presence of coronary artery disease [21] and the
occurrence of acute coronary syndrome [22].
Schnabel  et al. [23] showed that circulating 
ADMA adds independent prognostic information 
in patients with CAD. Valkonen et al. [21]
demonstrated that high concentrations of ADMA
in serum are associated with an increased risk of
acute coronary events among non-smoking middle-
aged men, especially in men with previous coronary
heart disease. A recent study in patients with 
acute MI reported that the baseline ADMA level 
has prognostic value for mortality after acute
myocardial infarction [24]. Asymmetrical
dimethylarginine was not associated with future
cardiovascular events in the present study. This
could be explained by the fact that our study
sample was small and all male. Meinitzer et al. [25]
demonstrated that ADMA concentrations predict
all-cause and cardiovascular mortality in individuals
with stable and acute CAD. A difference of their
study was inclusion of patients with stable CAD.
Our trial is the first study in the literature to
investigate whether severity of ED predicts major
cardiovascular events in patients with coronary
artery disease with ACS. Vascular disease and 
ED have similar pathogenic involvement of the 
nitric oxide pathway leading to impairment of
endothelium dependent vasodilatation and
structural vascular abnormalities [26, 27]. Montorsi
et al. identified ED as a predictor of acute coronary
syndromes [28]. They showed that ED occurred
before CAD symptoms in 67% of patients with ED.
Thus, they reinforced that ED might predict the
presence of subclinical vulnerable plaque. Ponholzer
et al. [29] showed that moderate-to-severe ED was
calculated to increase the 10-year relative risk of
developing CAD by 65% and stroke by 43%. Another
trial showed that ED significantly predicted cardiac
events [30]. Montorsi et al. [9] found that severe ED
was more frequent in patients with multi-vessel as
compared to single vessel disease. Thus, severe ED
should raise questions about prognosis in patients
with CAD. We found that severity of ED did not
predict future cardiovascular events in patients with
ACS. Recently published data have demonstrated
that ED is a powerful predictor of cardiovascular
morbidity and mortality in diabetic patients with
silent CAD [31]. Large prospective studies are
necessary to evaluate whether ED predicts
cardiovascular events in patients with ACS. 
Our study is limited by the relatively small
sample size. The relatively small number of male
patients could be the reason why ADMA and
severity of ED are not predictive in our study. Bae
et al. [32] found a significant decrease in ADMA
levels after 2 weeks of medical therapy for ACS.
Because of this we took blood samples within 
1 week after diagnosis of ACS before coronary
angiography. Although the majority of published
methods for determination of plasma
concentrations of ADMA are based on high
performance liquid chromatography (HPLC), we
determined ADMA by a recently atracted ELISA
method that is suitable for the determination of
Hazard ratio P value
(95% CI)
ADMA < 0.32 µmol/l 1
ADMA  ≥ 0.32 µmol/l 2.018 (0.615-6.626) 0.247
Table III. Cox regression analysis assessing the
multivariate hazard ratio for ADMA
Cut-off value 0.32 Umol/l according to ROC analysis (sensitivity 70%,
specificity 27%). Multivariate model: adjustment for age, total
cholesterol, LDL cholesterol, fasting blood glucose and Gensini score
Hazard ratio P value
(95% CI)
No ED (IIEF score 26 to 30) 1
Mild ED 0.259 (0.041-1.610) 0.147
(IIEF score 22 to 25)
Mild to moderate ED 0.605 (0.095-3.843) 0.594
(IIEF score 17 to 21)
Moderate ED 0.980 (0.233-4.121) 0.978
(IIEF score 11 to 16)
Severe ED 0.473 (0.052-1.345) 0.508
(IIEF score 1 to 10)
Table IV.  Cox regression analysis assessing the
multivariate hazard ratio for IIEF scoring
Multivariate model: adjustment for age, diabetes mellitus, current
smoking, oral antidiabetic therapy
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ADMA in large sample series to be analysed more
quickly than HPLC [33]. It may be a limitation of our
study. Additionally, only male patients participated
in the study, which is a further limitation. A recent
study found that a 0.15 µmol/l increase in baseline
ADMA levels was associated with approximately
30% increase in incident cardiovascular risk in 880
healthy women [34]. However, whether ADMA
concentrations are different in males and females
with ACS is not known. After performing power
analysis in our study we considered that large
prospective studies, also including female patients,
are necessary to evaluate whether ADMA predicts
cardiovascular events in patients with ACS. 
In conclusion, the results of this prospective
study suggest that ADMA and severity of ED did
not predict future cardiovascular events in this
patient group. Larger prospective studies with
longer follow-up are necessary to evaluate whether
ADMA and ED predict MACE in patients with ACS. 
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